Kevin began his career as a management consultant at Bain & Company focusing on technology, healthcare, and private equity clients. Since then, he has worked to improve public health in developing countries. Through the Clinton Health Access Initiative, he advised vaccine companies, multilateral institutions, and governments on strategies for developing and procuring vaccines for emerging markets. At Gates Ventures, Bill Gates’s private office, he led policy research efforts in child health and malnutrition.
Kevin combines his passion for healthcare access with a keen interest in innovation. He worked in portfolio management and late stage R&D strategy at Genentech, focusing on oncology and organizational decision making, and consults on business development projects with Stanford’s Office of Technology Licensing. Kevin also serves on the leadership of the Stanford Biotechnology Group and as an analyst for Mythos, a graduate student-run public equities biotech fund. He is an alumnus of Stanford’s Biodesign program, through which he designed an ultrasound-based device to improve accuracy of blood pressure monitoring.
Kevin is currently an MBA student at the Stanford Graduate School of Business. He holds a Bachelor’s degree in Ethics, Politics, and Economics, as well as a Master’s degree in Public Health, both from Yale University.
AMV is a venture capital firm investing in
early-stage digital health, technology and
life sciences companies.
2595 E Bayshore Rd, Suite 240
Palo Alto, CA
© 2019 Asset Management Ventures
All Rights Reserved